Treatment of schizophrenia with a vasopressin analogue.
Ten patients with chronic schizophrenia completed a 3-month double-blind, placebo-controlled trial with a vasopressin analogue. Modest improvement occurred, but several patients also experienced significant fluid and electrolyte imbalance.
D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003894:Deamino Arginine Vasopressin / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D014883:Water-Electrolyte Imbalance / Q000139:chemically induced
D010919:Placebos; D003894:Deamino Arginine Vasopressin